Two top-rated midsized drugmakers delivered sharply different third-quarter reports Tuesday, sending their stocks in opposite directions. Jazz Pharmaceuticals (JAZZ), reporting after the close, said earnings rose 31% over the year-earlier quarter to $2.33 a share, beating the consensus view by 11 cents, according to Thomson Reuters. Sales climbed 32% to $306.6 million, about $4 million above analysts’ estimates. The company
Today’s Screen of the Day features four institutional-quality drug and medical Big Caps stocks with solid fundamentals. Jazz Pharmaceuticals (JAZZ), which has a market cap of $9.85 billion, earned an IBD Composite Rating of 99, which means that it has outperformed 99% of all stocks in key metrics such as earnings and sales. Best-selling narcolepsy medication Xyrem made up two-thirds of Jazz’s second-quarter sales. The company acquired Italian
Some of the fattest annual profit margins come from drugmakers whose products are meant to make people healthier. Today’s Screen of the Day is Healthy Profit Margin and includes four highly rated drug stocks. Don’t miss out on Jazz Pharmaceuticals (JAZZ) and its annual profit margin of 54.4%. Its narcolepsy treatment, Xyrem, has rocketed to success and contributed to 65% of the drugmaker’s 2013 revenue. The company has an IBD Composite Rating of